头孢噻肟钠舒巴坦钠联合阿奇霉素与莫西沙星治疗社区获得性肺炎的疗效及经济性对比研究  

Comparison of Efficacy and Economy of Cefotaxime Sodium Sulbactam Sodium Combined with Azithromycin and Moxifloxacin in the Treatment of Community Acquired Pneumonia

作　　者：揭琼 万盟[1] 朱余兵[1] JIE Qiong;WAN Meng;ZHU Yubing(Dept.of Pharmacy,Nanjing First Hospital,Nanjing Medical University,Jiangsu Nanjing 210006,China)

机构地区：[1]南京医科大学附属南京医院(南京市第一医院)药学部,江苏南京210006

出　　处：《中国医院用药评价与分析》2021年第4期451-454,458,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：江苏省药学会-天晴临床药学基金科研项目(No.Q2019015)。

摘　　要：目的:探讨头孢噻肟钠舒巴坦钠联合阿奇霉素与莫西沙星治疗社区获得性肺炎(community acquired pneumonia,CAP)患者的疗效及经济性,为临床治疗CAP用药提供建议和参考。方法:采用前瞻性研究方法,收集2019年1—6月南京医科大学附属南京医院收治的CAP住院患者资料,将采用头孢噻肟钠舒巴坦钠联合阿奇霉素治疗者作为观察组(n=68),将采用莫西沙星治疗者作为对照组(n=82)。观察两组患者的治疗效果、不良反应和成本等,对两组方案的疗效及经济性进行评价。结果:(1)基线方面,两组患者性别、是否吸烟、近7 d内是否使用过抗菌药物及医保类型等资料的差异无统计学意义(P>0.05),但在年龄、是否饮酒及是否有慢性疾病方面的差异均有统计学意义(P<0.05)。(2)临床疗效方面,观察组患者的有效率为91.2%(62/68),对照组为91.5%(75/82),两组比较,差异无统计学意义(P>0.05)。采用Logistic多元回归模型进行分析,组别、性别、年龄、是否吸烟、是否饮酒、是否有慢性疾病和近7 d内是否使用过抗菌药物对疗效无显著影响。(3)住院时间方面,观察组患者的住院时间为8~10 d,中位时间为9 d;对照组患者的住院时间为6~8 d,中位时间为7 d,两组患者住院时间比较的差异有统计学意义(P<0.05)。(4)不良反应方面,观察组患者的不良反应发生率为16.2%(11/68),对照组为4.9%(4/82),两组患者不良反应发生率比较,差异有统计学意义(P<0.05)。(5)总成本方面,观察组患者的总成本为13608.76元,对照组为8399.53元,对照组患者的总成本显著低于观察组,差异有统计学意义(P<0.05)。(6)经济性分析,由于两组患者有效率的差异无统计学意义(P>0.05),故采用最小成本法直接比较两组方案的总成本进行经济性评价,结果显示,对照组方案更经济。结论:头孢噻肟钠舒巴坦钠联合阿奇霉素与莫西沙星在治疗CAP方面的疗效相当,但莫西沙星更经济。OBJECTIVE:To probe into the efficacy and economy of cefotaxime sodium sulbactam sodium combined with azithromycin and moxifloxacin in the treatment of community acquired pneumonia(CAP),so as to provide suggestions and references for the clinical treatment of CAP.METHODS:Prospective study method was used to collect the data of hospitalized patients with CAP in Nanjing First Hospital,Nanjing Medical University from Jan.to Jun.2019.The observation group(n=68)was treated with cefotaxime sodium sulbactam sodium and azithromycin,while the control group(n=82)received moxifloxacin.The treatment effects,adverse drug reactions and cost of two groups were observed,and the efficacy and economy were evaluated.RESULTS:(1)There were no statistically significant differences in gender,smoking status,use of antibiotics in the past 7 d and types of medical insurance between two groups(P>0.05),but there were statistically significant differences in age,drinking status and chronic diseases(P<0.05).(2)In terms of clinical efficacy,the effective rate was 91.2%(62/68)in the observation group and91.5%(75/82)in the control group,there was no significant difference between two groups(P>0.05).Logistic multiple regression model showed that group,gender,age,smoking status,drinking status,chronic disease and use of antibiotics win the past 7 d had no significant effect on the efficacy.(3)In terms of length of stay,the length of stay in the observation group was 9(8-10)d,and that in the control group was 7(6-8)d,there was statistically significant difference between two groups(P<0.05).(4)The incidence of adverse drug reactions in the observation group was 16.2%(11/68),and that in the control group was 4.9%(4/82),with statistically significant difference(P<0.05).(5)The total cost of the observation group was 13608.76 yuan,and that of the control group was8399.53 yuan,the total cost of the control group was significantly lower than that of the observation group,with statistically significant difference(P<0.05).(6)Due to there was no statistically

关 键 词：社区获得性肺炎 头孢噻肟钠舒巴坦钠 莫西沙星 疗效及经济性 

分 类 号：R978.1[医药卫生—药品]